Detalles de la búsqueda
1.
Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.
Oncologist
; 29(1): 25-35, 2024 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37523661
2.
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
Gynecol Oncol
; 186: 182-190, 2024 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38718741
3.
Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.
Lancet Oncol
; 22(9): 1312-1321, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34416158
4.
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lancet Oncol
; 22(7): 946-958, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34143969
5.
OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma.
Future Oncol
; 17(32): 4249-4261, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34382412
6.
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
Eur Urol
; 85(3): 229-238, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37778952
7.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
J Clin Oncol
; 42(11): 1222-1228, 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38227898
8.
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.
J Thorac Oncol
; 2023 Dec 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38159809
9.
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
Front Oncol
; 13: 1223282, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37664025
10.
Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
Front Oncol
; 13: 1343027, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38495081
11.
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.
Expert Rev Anticancer Ther
; 22(4): 383-400, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35260027
12.
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Eur J Cancer
; 173: 71-90, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35863108
13.
Positively selected modifications in the pore of TbAQP2 allow pentamidine to enter Trypanosoma brucei.
Elife
; 92020 08 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32762841
Resultados
1 -
13
de 13
1
Próxima >
>>